# A Phase 3 Study of Efficacy and Safety of AK101 in Subjects With Psoriasis

> **NCT05120297** · PHASE3 · COMPLETED · sponsor: **Akeso** · enrollment: 452 (actual)

## Conditions studied

- Psoriasis Vulgaris

## Interventions

- **DRUG:** AK101
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05120297
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-29
- **Primary completion:** 2022-09-29
- **Final completion:** 2022-09-29
- **Target enrollment:** 452 (ACTUAL)
- **Last updated:** 2023-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05120297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05120297, "A Phase 3 Study of Efficacy and Safety of AK101 in Subjects With Psoriasis". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05120297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*